Factor | Total tested | Rubella IgM | ||
---|---|---|---|---|
Positive | Negative | Equivocal | ||
n (%) | n (%) | n (%) | n (%) | |
Total sample | 4497 (100) | 1313 (29.2) | 2928 (65.1) | 256 (5.7) |
Sex | ||||
Male | 2333 (100) | 647 (27.7) | 1545 (66.2) | 141 (6.0) |
Female | 2160 (100) | 666 (30.8) | 1379 (63.8) | 115 (5.3) |
Age (years) | ||||
< 1 | 254 (100) | 19 (7.5) | 230 (90.6) | 5 (2.0) |
1–4 | 1336 (100) | 278 (20.8) | 1001 (74.9) | 57 (4.3) |
5–9 | 1322 (100) | 475 (35.9) | 744 (56.3) | 103 (7.8) |
10–14 | 739 (100) | 309 (41.8) | 380 (51.4) | 50 (6.8) |
15–24 | 414 (100) | 126 (30.4) | 263 (63.5) | 25 (6.0) |
25+ | 114 (100) | 14 (12.3) | 94 (82.5) | 6 (5.3) |
Month | ||||
January | 238 (100) | 52 (21.8) | 178 (74.8) | 8 (3.4) |
February | 300 (100) | 43 (14.3) | 248 (82.7) | 9 (3.0) |
March | 342 (100) | 57 (16.7) | 273 (79.8) | 12 (3.5) |
April | 282 (100) | 37 (13.1) | 235 (83.3) | 10 (3.5) |
May | 310 (100) | 27 (8.7) | 268 (86.5) | 15 (4.8) |
June | 307 (100) | 65 (21.2) | 229 (74.6) | 13 (4.2) |
July | 435 (100) | 169 (38.9) | 240 (55.2) | 26 (6.0) |
August | 432 (100) | 169 (39.1) | 233 (53.9) | 30 (6.9) |
September | 490 (100) | 166 (33.9) | 297 (60.6) | 27 (5.5) |
October | 552 (100) | 244 (44.2) | 263 (47.6) | 45 (8.2) |
November | 528 (100) | 204 (38.6) | 279 (52.8) | 45 (8.5) |
December | 281 (100) | 80 (28.5) | 185 (65.8) | 16 (5.7) |
Year | ||||
2005 | 580 (100) | 190 (32.8) | 342 (59.0) | 48 (8.3) |
2006 | 237 (100) | 72 (30.4) | 151 (63.7) | 14 (5.9) |
2007 | 425 (100) | 101 (23.8) | 299 (70.4) | 25 (5.9) |
2008 | 731 (100) | 255 (34.9) | 421 (57.6) | 55 (7.5) |
2009 | 316 (100) | 76 (24.1) | 239 (75.6) | 1 (0.3) |
2010 | 357 (100) | 16 (4.5) | 334 (93.6) | 7 (2.0) |
2011 | 175 (100) | 62 (35.5) | 99 (56.6) | 14 (8.0) |
2012 | 341 (100) | 150 (44.0) | 165 (48.4) | 26 (7.6) |
2013 | 358 (100) | 177 (49.4) | 147 (41.1) | 34 (9.5) |
2014 | 284 (100) | 87 (30.6) | 187 (65.8) | 10 (3.5) |
2015 | 394 (100) | 98 (24.9) | 281 (71.3) | 15 (3.8) |
2016 | 299 (100) | 29 (9.7) | 263 (88.0) | 7 (2.3) |